SciClone Pharmaceuticals Inc
Audrey Wu has worked in the pharmaceutical industry for several companies. Their most recent position was as the Associate Director of Medical Affairs at SciClone Pharmaceuticals, starting in January 2018. Prior to that, they held the role of Senior Medical Affairs Manager at the same company from July 2017 to December 2017, and they were a Medical Affairs Manager from March 2015 to June 2017. Before joining SciClone Pharmaceuticals, Audrey worked at Roche as a Medical Scientific Liaison from March 2013 to March 2015. Audrey also had experience at Bayer, where they held the positions of Associate Product Manager from August 2011 to March 2013 and Medical Representative from November 2010 to July 2011.
From 2007 to 2010, Audrey Wu attended Shanghai Jiao Tong University, where they pursued a dual degree in General Surgery and Liver Transplantation. Audrey obtained a PhD and MD during this period.
This person is not in the org chart
This person is not in any offices
SciClone Pharmaceuticals Inc
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.